ArticleNPJ breast cancer2025
PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Redefining breast cancer: therapeutic opportunities in HER2-low and emerging molecular subtypes.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
PARG plays an important role in cancer progression and immunoresponse, but its role in breast cancer is not yet fully elucidated. The advanced breast cancer is still a persistent challenge in clinical oncology. Despite the encouraging progress made in cancer immunotherapy, its efficacy is still limited by tumor malignancy and the immunosuppressive microenvironment. Through comprehensive proteomic analysis employing liquid chromatography-tandem mass spectrometry, we identified ITCH-a HECT-family E3 ubiquitin ligase-as a novel interaction partner of PARG. Co-immunoprecipitation and ubiquitination assays revealed that the PARG inhibition markedly enhances the PARylation of the E3 ubiquitin ligase ITCH. This triggers its autoubiquitination-dependent activation, after which activated ITCH catalyzes the ubiquitination of the oncoprotein metadherin (MTDH). This ultimately leads to MTDH's proteasomal degradation and the consequent suppression of tumor growth. Importantly, RNA immunoprecipitation analysis further demonstrated that PARGi-induced ITCH/MTDH potentiates the MHC-I antigen presentation machinery in tumor cells, which correlates with increased infiltration of cytotoxic T lymphocytes within the tumor microenvironment. In invivo validation, combinatorial therapy using the selective PARG inhibitor COH34 with anti-PD-L1 immune checkpoint blockade demonstrated synergistic therapeutic efficacy in a murine breast cancer model. To the best of our knowledge, PARG inhibition plays an important role in limiting cancer progression and potentiating immune response, depending on its regulatory function in PARylation and ubiquitination in breast cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.